Q1 Earnings Estimate for CVKD Issued By Zacks Small Cap

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Equities research analysts at Zacks Small Cap issued their Q1 2025 earnings per share estimates for Cadrenal Therapeutics in a research report issued to clients and investors on Monday, March 31st. Zacks Small Cap analyst D. Bautz expects that the company will post earnings of ($1.13) per share for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.59) per share. Zacks Small Cap also issued estimates for Cadrenal Therapeutics’ Q2 2025 earnings at ($1.24) EPS, Q3 2025 earnings at ($1.43) EPS, Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($5.30) EPS and FY2027 earnings at ($1.57) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($2.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.71) by ($1.03).

Cadrenal Therapeutics Stock Performance

Shares of Cadrenal Therapeutics stock opened at $17.67 on Wednesday. The company has a market capitalization of $33.22 million, a PE ratio of -2.65 and a beta of 1.40. The company has a 50-day simple moving average of $18.75 and a two-hundred day simple moving average of $16.06. Cadrenal Therapeutics has a one year low of $5.40 and a one year high of $22.90.

Hedge Funds Weigh In On Cadrenal Therapeutics

An institutional investor recently bought a new position in Cadrenal Therapeutics stock. Geode Capital Management LLC purchased a new position in shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 10,554 shares of the company’s stock, valued at approximately $153,000. Geode Capital Management LLC owned 0.59% of Cadrenal Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 7.92% of the company’s stock.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.